Affiliated with a Castle Connolly Top Hospital
Who is Dr. Berek, Gynecologic Oncologist in Stanford, CA?
Dr. Jonathan Berek, MD is a Gynecologic Oncologist, who primarily practices in Stanford, CA with 1 additional practice location. He is board certified. Dr. Berek completed his residency at Harvard Medical School Brigham and Women's Hospital. Dr. Berek is fluent in English and Spanish, and is currently seeing new patients. Dr. Berek’s practice accepts Medicare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Berek’s office at (650) 723-4000.
What are Areas of Expertise for Dr. Berek?
Dr. Jonathan Berek, MD is a highly-rated, board-certified Gynecologic Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Berek empowers patients to confidently navigate their health journey, specializing in Cervical Cancer, Gestational Trophoblastic Disease, Ovarian Cancer, Uterine Cancer, Vulvar & Vaginal Cancer, and comprehensive wellness support. Serving the Stanford, CA community, Dr. Berek is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Berek go to medical school and complete their residency?
Fellowship: UCLA
Residency: Harvard Medical School Brigham and Women's Hospital
Is Dr. Berek board certified as a Gynecologic Oncologist?
Yes, Dr. Jonathan Berek, MD is board certified by the American Board of Obstetrics and Gynecology , American Board of Obstetrics and Gynecology since 1983
What languages does Dr. Berek speak?
Dr. Berek and their clinical team can communicate with patients in the following languages:
English
Spanish
What conditions does a Gynecologic Oncologist like Dr. Berek typically treat?
As a Gynecologic Oncologist, Dr. Berek diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Berek. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Ovarian Cancer
- Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ)
- Cancer of the ovary
- Ovarian carcinoma
- Female reproductive cancer
ICD-10 Codes:
- C569: Malignant neoplasm of unspecified ovary
What procedures does a Gynecologic Oncologist like Dr. Berek typically perform?
As a Gynecologic Oncologist, procedures performed by Dr. Jonathan Berek may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
Please contact Dr. Berek's office directly to confirm care for your specific procedure, for more information, or to schedule a consultation.
Does Dr. Berek accept my insurance?
Dr. Berek accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Berek accept in Stanford, CA?
Dr. Berek in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
CVS Health (formerly Aetna)
Medicare
UnitedHealth Group
Unknown
View All Insurances
Where is Dr. Berek's office located?
Recognitions
Publications
Abagovomab As Maintence Therapy in Patients With Epithelial Ovarian Cancer
, 2013
Cancer of the ovary, fallopian tube, and peritoneum
, 2012
FOXO3 siglling links ATM to the p53 apoptotic pathway following D damage
, 2012
Current Magement of Vulvar Cancer
, 2012
Persolizing CA125 Levels for Ovarian Cancer Screening
, 2011
Strategies and Goals
, 2010
Survival After Second
, 2009
Oregovomab Maintence Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
, 2009
Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid
, 2008
Trends in demographic and clinical characteristics in women
, 2008
CA125 velocity at relapse is a highly significant predictor of survival post relapse
, 2008
Vulvar melanoma - A multivariable alysis of 644 patients
, 2007
Impact of the human papilloma vaccine on cervical cancer
, 2007
The potential therapeutic role of lymph node resection in epithelial ovarian cancer
, 2007
Elective oophorectomy for benign gynecological disorders
, 2007
Prognostic factors responsible for survival in sex cord stromal tumors of the ovary
, 2007
Ovarian cancer in younger vs older women: a population-based alysis
, 2006
Progress in ovarian cancer research
, 2006
An alysis of surgical versus chemotherapeutic intervention
, 2006
Pelvic exenteration for recurrent gynecologic maligncy
, 2005
Design, conduct and evaluation of a communication course for oncology fellows
, 2005
Lower uriry tract reconstruction with ileum in. the treatment of gynecologic maligncies
, 2005
Monoclol antibody therapy of ovarian cancer
, 2005
Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in
, 2004
Using fresh tissue dissection to teach human atomy in the clinical years
, 2004
Current research and treatment for epithelial ovarian cancer
, 2003
Cervical cancer: An opportunity to prevent and cure
, 2003
Progress in the magement of gynecologic cancer: consensus summary statement.
Biologic and immunologic therapies for ovarian cancer.
, 2003
Surgical resection of solitary brain metastasis from cervical cancer
, 2003
The use of continuous infusion topotecan in persistent and recurrent ovarian cancer
, 2003
CA125 levels are a weak predictor of optimal cytoreductive surgery
, 2003
Simplification of the new Bethesda 2001 classification System
, 2003
FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival
, 2002
Advances in the magement of epithelial ovarian cancer
, 2001
A radical debulking of leiomyomatosis peritonealis dissemita from a colonic obstruction
, 2000
Ovarian cancer: Epidemiology, biology, and prognostic factors
, 2000
Concurrent chemotherapy
, 2000
Fraud. What is the evidence?
, 2000
IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites
, 1999
Intraperitoneal alpha-interferon alterting with cisplatin in residual ovarian carcinoma
, 1999
Combition of transforming growth factor beta antisense
, 1998
Gene therapy for ovarian cancer: Development of novel treatment strategies
, 1997
Complete debulking of epithelial ovarian cancer.
, 1996
Mixed mesodermal sarcoma of the ovary in a young patient
, 1996
Evidence for a unifocal origin in familial ovarian cancer
, 1996
RADIATION-THERAPY FOR ADENOCARCINOMA OF THE UTERINE CERVIX - DOES THE HISTOLOGY MATTER
, 1995
ASSESSMENT OF DOSE-INTENSIVE THERAPY IN SUBOPTIMALLY DEBULKED OVARIAN
, 1995
INTERVAL DEBULKING OF OVARIAN-CANCER - AN INTERIM MEASURE
, 1995
Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial Intertiol
, 1995
A MULTICENTER STUDY OF LAPAROSCOPIC MAGEMENT OF SELECTED CYSTIC ADNEXAL MASSES IN POSTMENOPAUSAL
, 1994
PROGNOSTIC IMPORTANCE OF INTRAOPERATIVE RUPTURE OF MALIGNT OVARIAN EPITHELIAL NEOPLASMS
, 1994
Papillary serous cystadenocarcinoma arising in benign glandular inclusion cysts
, 1994
SURGICAL-MAGEMENT OF OVARIAN-CANCER
, 1994
MOLECULAR AND BIOLOGIC FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER
, 1994
LAPAROSCOPIC MAGEMENT OF THE ADNEXAL MASS
, 1994
Peritoneal adenocarcinoma (serous) of Müllerian type: a subgroup of women presenting with peritoneal
, 1994
Magement of Selected Adnexal Masses in Postmenopausal Women by Operative Laparoscopy
, 1994
Fine-needle aspiration cytology in the magement of gynecologic oncology patients.
, 1994
PRIMARY LEIOMYOSARCOMA OF THE OVARY IN A PERIMERCHAL FEMALE
, 1993
Current magement of invasive squamous carcinoma of the vulva.
, 1993
ADVANCED EPITHELIAL OVARIAN-CANCER - 1993 CONSENSUS STATEMENTS
, 1993
Advanced ovarian cancer. Tumour markers.
, 1993
PRESENCE OF INTERLEUKIN 10
, 1992
INTRAPERITONEAL IMMUNOTHERAPY FOR OVARIAN-CANCER WITH ALPHA-INTERFERON
, 1992
STIMULATION OF OVARIAN TUMOR-CELL PROLIFERATION WITH MONOCYTE PRODUCTS INCLUDING INTERLEUKIN-1
, 1992
2ND-LOOK VERSUS 2ND TURE
, 1992
ADNEXAL TORSION - AN UNUSUAL CAUSE OF ABDOMIL-PAIN IN POSTMENOPAUSAL WOMEN
, 1991
ASSESSMENT OF CURRENT INTERTIOL FEDERATION OF GYNECOLOGY AND OBSTETRICS
, 1991
Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer
, 2013
Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses'
, 2013
Cancer of the ovary, fallopian tube, and peritoneum
, 2012
FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage
, 2012
Current Management of Vulvar Cancer
, 2012
Personalizing CA125 Levels for Ovarian Cancer Screening
, 2011
Strategies and Goals
, 2010
Prophylactic and Risk-Reducing Bilateral Salpingo
, 2010
Lymph Node-Positive Stage IIIC Ovarian Cancer A Separate Entity?
, 2009
Ovarian Conservation at the Time of Hysterectomy
, 2009
Survival After Second
, 2009
Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
, 2009
HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review
, 2008
Opportunities and challenges in ovarian cancer research
, 2008
Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid
, 2008
Trends in demographic and clinical characteristics in women diagnosed with corpus cancer
, 2008
CA125 velocity at relapse is a highly significant predictor of survival post relapse
, 2008
Elective oophorectomy in the gynecological patient: when is it desirable?
, 2007
Vulvar melanoma - A multivariable analysis of 644 patients
, 2007
Impact of the human papilloma vaccine on cervical cancer
, 2007
The potential therapeutic role of lymph node resection in epithelial ovarian cancer
, 2007
Lymphadenectomy in endometrioid uterine cancer staging
, 2007
Influence of the gynecologic oncologist on the survival of ovarian cancer patients
, 2007
Ovarian conservation at the time of hysterectomy for benign disease
, 2007
Elective oophorectomy for benign gynecological disorders
, 2007
Prognostic factors for uterine cancer in reproductive-aged women
, 2007
CA125: Megadaltons of novel opportunities
, 2007
Prognostic factors responsible for survival in sex cord stromal tumors of the ovary
, 2007
Association of lymphadenectomy and survival in stage I ovarian cancer patients
, 2007
The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma
, 2006
Ovarian cancer in younger vs older women: a population-based analysis
, 2006
Response to commentaries on retention of the ovaries and long-term survival after hysterectomy
, 2006
Patterns and progress in ovarian cancer over 14 years
, 2006
Intraperitoneal chemotherapy for ovarian cancer
, 2006
Surgery for ovarian cancer: how to improve survival
, 2006
10th Biennial Helene Harris Memorial Trust Meeting
, 2006
Progress in ovarian cancer research
, 2006
An analysis of surgical versus chemotherapeutic intervention
, 2006
Pelvic exenteration for recurrent gynecologic malignancy
, 2005
Design, conduct and evaluation of a communication course for oncology fellows
, 2005
Lower urinary tract reconstruction with ileum in. the treatment of gynecologic malignancies
, 2005
Rethinking the use of radiation and chemotherapy after radical hysterectomy
, 2005
Monoclonal antibody therapy of ovarian cancer
, 2005
Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix
, 2005
Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in
, 2004
Using fresh tissue dissection to teach human anatomy in the clinical years
, 2004
Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab
, 2004
Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy
, 2004
Lymphovascular and perineural invasion in the parametria
, 2003
Current research and treatment for epithelial ovarian cancer
, 2003
Cervical cancer: An opportunity to prevent and cure
, 2003
Amifostine pretreatment for protection against topotecan-induced hematologic toxicity
, 2003
Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix
, 2003
Progress in the management of gynecologic cancer: consensus summary statement.
Biologic and immunologic therapies for ovarian cancer.
, 2003
Surgical resection of solitary brain metastasis from cervical cancer
, 2003
The use of continuous infusion topotecan in persistent and recurrent ovarian cancer
, 2003
CA125 levels are a weak predictor of optimal cytoreductive surgery
, 2003
Simplification of the new Bethesda 2001 classification System
, 2003
Specific keynote: Immunological therapy for ovarian cancer
, 2003
FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival
, 2002
Advances in the management of epithelial ovarian cancer
, 2001
A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction
, 2000
Interferon plus chemotherapy for primary treatment of ovarian cancer
, 2000
[Epithelial ovarian cancer (advanced stage): consensus conference (1998)].
Ovarian cancer: Epidemiology, biology, and prognostic factors
, 2000
Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125
, 2000
Concurrent chemotherapy
, 2000
Fraud. What is the evidence?
, 2000
IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites
, 1999
Endometrial cancer: Recent developments in evaluation and treatment
, 1999
Recurrent mature cystic teratoma presenting as a perihepatic mass
, 1999
Intraperitoneal interferon-alpha in residual ovarian carcinoma
, 1999
Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma
, 1999
Advanced epithelial ovarian cancer: 1998 consensus statements
, 1999
Basic research: how much do we know
, 1999
Surgery during chemotherapy and at relapse of ovarian cancer
, 1999
A phase II study of intraperitoneal cisplatin
, 1998
Combination of transforming growth factor beta antisense
, 1998
Psammocarcinoma with an aggressive course
, 1998
Reducing loss-to-follow-up among women with abnormal Pap smears - Results from a r
, 1998
Diagnostic and therapeutic advances in gynecologic oncology: screening for gynecologic cancer.
, 1998
Progress in ovarian cancer
, 1998
Gene therapy for ovarian cancer: Development of novel treatment strategies
, 1997
Dysgerminoma: The role of conservative surgery
, 1996
Complete debulking of epithelial ovarian cancer.
, 1996
Mixed mesodermal sarcoma of the ovary in a young patient
, 1996
Evidence for a unifocal origin in familial ovarian cancer
, 1996
Vascular endothelial growth factor expression is not regulated
, 1996
OVARIAN-CANCER SCREENING
, 1995
RADIATION-THERAPY FOR ADENOCARCINOMA OF THE UTERINE CERVIX - DOES THE HISTOLOGY MATTER
, 1995
OVARIAN-CANCER SPREAD - IS LAPAROSCOPY TO BLAME
, 1995
ASSESSMENT OF DOSE-INTENSIVE THERAPY IN SUBOPTIMALLY DEBULKED OVARIAN
, 1995
INTERVAL DEBULKING OF OVARIAN-CANCER - AN INTERIM MEASURE
, 1995
INTRAPERITONEAL ADMINISTRATION OF CISPLATIN AND 5-FLUOROURACIL IN RESIDUAL OVARIAN
, 1995
Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial International
, 1995
A MULTICENTER STUDY OF LAPAROSCOPIC MANAGEMENT OF SELECTED CYSTIC ADNEXAL MASSES
, 1994
PROGNOSTIC IMPORTANCE OF INTRAOPERATIVE RUPTURE OF MALIGNANT OVARIAN EPITHELIAL NEOPLASMS
, 1994
THE INFLUENCE OF TUMOR GRADE, DISTRIBUTION
, 1994
Papillary serous cystadenocarcinoma arising in benign glandular inclusion cysts
, 1994
Advances in the biology of gynecologic cancer.
, 1994
SALVAGE THERAPY FOR RECURRENT AND REFRACTORY OVARIAN-CANCER WITH HIGH
, 1994
SURGICAL-MANAGEMENT OF OVARIAN-CANCER
, 1994
MOLECULAR AND BIOLOGIC FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER
, 1994
CYTOKINE-INDUCED MODULATION OF TUMOR-SUPPRESSOR GENE-EXPRESSION IN OVARIAN-CANCER CELLS -
, 1994
CONSERVATIVE AND INDIVIDUALIZED SURGERY FOR EARLY SQUAMOUS CARCINOMA OF THE VULVA
, 1994
THE EFFECT OF DIAMETER OF LARGEST RESIDUAL DISEASE ON SURVIVAL AFTER PRIMARY CYTOREDUCTIVE SURGERY
, 1994
LAPAROSCOPIC MANAGEMENT OF THE ADNEXAL MASS
, 1994
UTERINE SARCOMA IN PATIENTS OPERATED ON FOR PRESUMED LEIOMYOMA AND RAPIDLY GROWING LEIOMYOMA
, 1994
Peritoneal adenocarcinoma (serous) of Müllerian type: a subgroup of women presenting with peritoneal
, 1994
Management of Selected Adnexal Masses in Postmenopausal Women by Operative Laparoscopy
, 1994
Fine-needle aspiration cytology in the management of gynecologic oncology patients.
, 1994
CONSTITUTIVE PRODUCTION OF MACROPHAGE-COLONY
, 1993
PROGNOSTIC FACTORS FOR GROIN NODE METASTASIS IN SQUAMOUS-CELL CARCINOMA OF THE VULVA
, 1993
IMPACT OF CONTRACEPTION ON GYNECOLOGIC CANCERS
, 1993
GROWTH-INHIBITION OF OVARIAN-CANCER CELLS INDUCED BY ANTISENSE IL-6 OLIGONUCLEOTIDES
, 1993
SOLITARY RECURRENT METASTASIS OF EPITHELIAL OVARIAN-CANCER IN THE SPLEEN
, 1993
PRIMARY LEIOMYOSARCOMA OF THE OVARY IN A PERIMENARCHAL FEMALE
, 1993
SENSITIVITY OF DRUG-RESISTANT HUMAN OVARIAN TUMOR
, 1993
Current management of invasive squamous carcinoma of the vulva.
, 1993
MOLECULAR AND BIOLOGICAL FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER
, 1993
ADVANCED EPITHELIAL OVARIAN-CANCER - 1993 CONSENSUS STATEMENTS
, 1993
Advanced ovarian cancer. Tumour markers.
, 1993
PRESENCE OF INTERLEUKIN 10
, 1992
BIOLOGIC AND IMMUNOLOGICAL THERAPY OF OVARIAN-CANCER
, 1992
INTRAPERITONEAL IMMUNOTHERAPY FOR OVARIAN-CANCER WITH ALPHA-INTERFERON
, 1992
CHARACTERISTICS OF PATIENTS WITH SMALL-VOLUME RESIDUAL OVARIAN
, 1992
IMPROVING ADHERENCE TO SCREENING FOLLOW-UP AMONG WOMEN WITH ABNORMAL PAP SMEARS
, 1992
STIMULATION OF OVARIAN TUMOR-CELL PROLIFERATION WITH MONOCYTE PRODUCTS INCLUDING INTERLEUKIN-1
, 1992
EARLY-STAGE SQUAMOUS-CELL AND ADENOCARCINOMA OF THE CERVIX
, 1992
2ND-LOOK VERSUS 2ND NATURE
, 1992
Interleukin 6 and cancer treatment.
, 1991
CONCURRENT CISPLATIN AND 5-FLUOROURACIL CHEMOTHERAPY AND RADIATION
, 1991
ADNEXAL TORSION - AN UNUSUAL CAUSE OF ABDOMINAL-PAIN IN POSTMENOPAUSAL WOMEN
, 1991
ASSESSMENT OF CURRENT INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS STAGING OF VULVAR
, 1991
SERUM INTERLEUKIN-6 LEVELS CORRELATE WITH DISEASE STATUS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER
, 1991
A PHASE I-II TRIAL OF INTRAPERITONEAL CISPLATIN AND ALPHA
, 1991
FINE-NEEDLE ASPIRATION CYTOLOGY ACCURACY WITH PALPABLE GYNECOLOGIC NEOPLASMS
, 1991
What is Dr. Berek's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Berek's National Provider Identifier (NPI) number is 1164447900.
What common questions do patients ask about Dr. Berek?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Berek
What is Dr. Jonathan Berek's specialty?
Dr. Berek is a Gynecologic Oncologist near Stanford, CA.
What does a Gynecologic Oncologist do?
An obstetrician/gynecologist specializing in gynecologic oncology provides consultation and comprehensive management for patients with gynecologic cancer. This includes performing diagnostic and therapeutic procedures essential for the total care of patients with gynecologic cancer and addressing any resulting complications.
Is this Dr. Jonathan Berek affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Berek is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Gynecologic Oncologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Gynecologic Oncologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Jonathan Berek accepting new patients in Stanford, CA?
Yes, Dr. Jonathan Berek is accepting new patients at this time.
Does Dr. Jonathan Berek offer online booking?
Please contact Dr. Berek's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Jonathan Berek?
Please contact Dr. Berek's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Jonathan Berek have?
Dr. Jonathan Berek is certified by the American Board of Obstetrics and Gynecology.
Other Gynecologic Oncologist Near Stanford, CA
Gynecologic Oncologist
Accepting patientsGynecologic Oncologist
Accepting patientsGynecologic Oncologist
Accepting patients